BioSpace News Archive

Ra Medical Systems, Inc. announces enrollment has reached 95 subjects in its pivotal clinical trial to evaluate the safety and effectiveness of the DABRA excimer laser system as an atherectomy device for the treatment of peripheral arterial disease (PAD).

Cara Therapeutics, Inc. today announced the Company will host a virtual research and development (R&D) event on Friday, March 11, 2022, from 1:00 to 2:00 p.m. ET.

Alofisel ® ▼ (darvadstrocel) Shows Clinical Remission Rate at Six-Months in the Real-World INSPIRE Study Interim Analysis Consistent with the Pivotal Clinical ADMIRE-CD Study.

Plus Therapeutics, Inc. announced that the Company will report fourth quarter and full year 2021 financial results on Thursday, February 24, 2022, after market close.

Sibannac, Inc. announced the following: David Mersky, CEO of Sibannac, Inc., joins New to the Street anchor, Jane King, in an interview to discuss the Company’s entry into the alternative wellness space.

Nevro Corp. announced that D. Keith Grossman, Nevro’s Chairman, CEO and President, Rod MacLeod, Chief Financial Officer, and Dr. David Caraway, Chief Medical Officer, will participate in the Wells Fargo 2022 MedTech R&D Spotlight Call Series on Friday, March 4, 2022 at 10:00 am Eastern Time.

Bruker Corporation announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company’s common stock.

Dante Labs today announced it has partnered with The Renato Dulbecco Foundation to deliver more personalized therapies in rare diseases, oncology and COVID-19.

Acerus Pharmaceuticals Corporation (the “ Company ” or “ Acerus ”) (TSX:ASP; OTCQB:ASPCF) today announced that it has entered into an amending agreement with First Generation Capital Inc. (“ First Generation ”), a company affiliated with the Chairman of the Board of Directors of Acerus 1 , to increase its secured loan facility (the “ Loan Facility ”) from US$25 million to US$30.845 million.

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in AROC3-1001, a Phase 1/2 clinical study of ARO-C3, the company’s investigational RNA interference (RNAi).